@article{004b95be644f43f4bb4e10118ff09ddc,
title = "A Multicenter, Prospective, Observational Study to Determine the Incidence of Febrile Neutropenia (FN), Persistence and G-CSF Utilization Among Cancer Patients at High Risk for FN Receiving Pegfilgrastim by an On-body Injector (OBI) versus other FN Prophylaxis Strategies: An Interim Analysis",
abstract = " J. Crawford; R. Rifkin; D. Dale; A. Brookhart; P. Gawade; S. Lewis; T. Lawrence; R. Belani; G. Lyman ",
author = "Reshma Mahtani",
note = "Abstract. Background Pegfilgrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) shown to effectively reduce the risk of chemotherapy-induced FN. Pegfilgrastim should be administered on the day after chemotherapy completion (Lyman, Cancer, 2017). For patient convenience, an OBI was developed to deliver pegfilgrastim 27 hours after OBI application on the day of chemotherapy.",
year = "2021",
month = feb,
day = "15",
language = "American English",
volume = "81",
journal = "Cancer Research / San Antonio Breast Cancer Symposium",
}